The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells

Cancer Gene Therapy

Volumn 16, Issue 3, 2009, Pages 237-245

  Katsura, T ^a   Iwai, S ^a   Ota, Y ^a   Shimizu, H ^a   Ikuta, K ^b   Yura, Y ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Deacetylase inhibitor; Herpes simplex virus mutant; Histone; NF B; Oncolytic virotherapy

Indexed keywords

BETA GALACTOSIDASE; GLYCOPROTEIN D; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ONCOLYTIC HERPES VIRUS; PROTEIN P21; SN 50; SYNAPTOTAGMIN I; TRICHOSTATIN A;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL VIABILITY; CONTROLLED STUDY; DNA BINDING; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; MOUTH CARCINOMA; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN TRANSPORT; SQUAMOUS CELL CARCINOMA; UPREGULATION; VIROTHERAPY; VIRUS REPLICATION; VIRUS STRAIN;

ACETYLATION; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DEFECTIVE VIRUSES; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 1, HUMAN; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; MOUTH NEOPLASMS; NEOPLASM PROTEINS; NF-KAPPA B; ONCOLYTIC VIROTHERAPY; PEPTIDES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; TRANSCRIPTION FACTOR RELA; VIRAL PROTEINS; VIRUS ACTIVATION; VIRUS REPLICATION;

HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 60149097656     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.81     Document Type: Article

References (38)

1. Kirn D, Marutuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001; 7: 781-787.
2. MacLean AR, ul-Fareed M, Robertson L, Harland J, Brown SM. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J Gen Virol 1991; 72: 631-639.
3. Chou J, Kern ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 1990; 250: 1262-1266.
4. Chahlavi A, Todo T, Martuza RL, Rabkin SD. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1999; 1: 162-169.
5. Fu X, Tao L, Jin A, Vile R, Brenner MK, Zhang X. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther 2003; 7: 748-754.
6. Aghi M, Rabkin S, Martuza RL. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst 2006; 98: 38-50.
7. McKee TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res 2006; 66: 2509-2513.
8. Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Canron X et al. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res 2006; 12: 6791-6799.
9. Naito S, Obayashi S, Sumi T, Iwai S, Nakazawa M, Ikuta K et al. Enhancement of antitumor activity of herpes simplex virus g134.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide. Cancer Gene Ther 2006; 13: 780-791.
10. Baldwin Jr AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-683.
11. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-260.
12. Adam E, Quivy V, Bex F, Chariot A, Collette Y, Vanhulle C et al. Potentiation of tumor necrosis factor-induced NF-kappa B activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearance of I kappa B alpha. Mol Cell Biol 2003; 23: 6200-6209.
13. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004; 18: 2195-2224.
14. Israël A. The IKK complex: an integrator of all signals that activate NF-kappaB? Trends Cell Biol 2000; 10: 129-133.
15. Jung M. Inhibitors of histone deacetylase as new anticancer agents. Curr Med Chem 2001; 8: 1505-1511.
16. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1: 194-202.
17. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-784.
18. Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2007; 6: 37-50.
19. Kim DH, Lee J, Kim KN, Kim HJ, Jeung HC, Chung HC et al. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor. Biochem Biophys Res Commun 2007; 356: 233-238.
20. Chen L, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 2001; 293: 1653-1657.
21. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 2001; 7: 971-976.
22. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini C. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 2003; 278: 12579-12589.
23. Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, Yu Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA 2005; 102: 16090-16095.
24. Patel A, Hanson J, McLean TI, Olgiate J, Hilton M, Miller WE et al. Herpes simplex type 1 induction of persistent NFkappa B nuclear translocation increases the efficiency of virus replication. Virology 1998; 247: 212-222.
25. Amici C, Rossi A, Costanzo A, Ciafre S, Marinari B, Balsamo M et al. Herpes simplex virus disrupts NF-kappaB regulation by blocking its recruitment on the IkappaBalpha promoter and directing the factor on viral genes. J Biol Chem 2006; 281: 7110-7117.
26. Goodkin ML, Ting AT, Blaho JA. NF-kappaB is required for apoptosis prevention during herpes simplex virus type 1 infection. J Virol 2003; 77: 7261-7280.
27. Taddeo B, Luo TR, Zhang W, Roizman B. Activation of NF-kappaB in cells productively infected with HSV-1 depends on activated protein kinase R and plays no apparent role in blocking apoptosis. Proc Natl Acad Sci USA 2003; 100: 12408-12413.
28. Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY et al. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 1997; 57: 1502-1509.
29. Starenki D, Namba H, Saenko V, Ohtsuru A, Yamashita S. Inhibition of nuclear factor-kappaB cascade potentiates the effect of a combination treatment of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2004; 89: 410-418.
30. Archer SY, Meng S, Shei A, Hodin RA. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 1998; 95: 6791-6796.
31. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000; 97: 10014-10019.
32. Smith KD, Mezhir JJ, Bickenbach K, Veerapong J, Charron J, Posner MC et al. Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Delta gamma(1)34.5 mutants of herpes simplex virus 1. J Virol 2006; 80: 1110-1120.
33. Chou J, Chen JJ, Gross M, Roizman B. Association of a M(r) 90 000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5-mutants of herpes simplex virus 1. Proc Natl Acad Sci USA 1995; 92: 10516-10520.
34. Gregory D, Hargett D, Holmes D, Money E, Bachenheimer SL. Efficient replication by herpes simplex virus type 1 involves activation of the IkappaB kinase-IkappaB-p65 pathway. J Virol 2004; 78: 13582-13590.
35. Honess RW, Roizman B. Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. J Virol 1974; 14: 8-19.
36. Mace AT, Ganly I, Soutar DS, Brown SM. Potential for efficacy of the oncolytic herpes simplex virus 1716 in patients with oral squamous cell carcinoma. Head Neck 2008; 30: 1045-1051.
37. Schang LM. Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication. Biochim Biophys Acta 2004; 1697: 197-209.
38. Liu TC, Castelo-Branco P, Rabkin SD, Martuza RL. Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol Ther 2008; 16: 1041-1047.